Online Impact
Statistics from Altmetric.com
ARTICLE USAGE
Cited By
Article Information
Volume 8, Issue 9, pp. 1114-1121
PubMed
Published By
Print ISSN
Online ISSN
History
- Received October 2, 2019
- Revision received March 19, 2020
- Accepted June 26, 2020
- Published first July 13, 2020.
Article Versions
- Previous version (July 13, 2020 - 06:51).
- Previous version (August 11, 2020 - 06:31).
- You are viewing the most recent version of this article.
Copyright & Usage
©2020 American Association for Cancer Research.
Author Information
- Jessica L.F. Teh1,
- Dan A. Erkes1,
- Phil F. Cheng2,
- Manoela Tiago1,
- Nicole A. Wilski1,
- Conroy O. Field1,
- Inna Chervoneva3,4,
- Mitch P. Levesque2,
- Xiaowei Xu5,
- Reinhard Dummer2, and
- Andrew E. Aplin1,4,*
- 1Department of Cancer Biology, Thomas Jefferson University, Philadelphia, Pennsylvania.
- 2Department of Dermatology, University of Zurich Hospital, Zurich, Switzerland.
- 3Division of Biostatistics, Department of Pharmacology and Experimental Therapeutics, Thomas Jefferson University, Philadelphia, Pennsylvania.
- 4Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania.
- 5Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
- ↵*Corresponding Author:
Andrew E. Aplin, Sidney Kimmel Cancer Center, Thomas Jefferson University, 233 South 10th Street, Philadelphia, PA 19107. Phone: 215-503-7296; Fax: 215-923-9248; E-mail: Andrew.Aplin{at}Jefferson.edu
September 2020
Volume 8, Issue 9
Volume 8, Issue 9
Activation of CD8+ T Cells Contributes to Antitumor Effects of CDK4/6 Inhibitors plus MEK Inhibitors
Jump to section
Advertisement